The development of the China-based company 'Systematic Review Solutions' and enhanced knowledge of evidence-based medicine
Submitting Institution
University of NottinghamUnit of Assessment
Psychology, Psychiatry and NeuroscienceSummary Impact Type
SocietalResearch Subject Area(s)
Medical and Health Sciences: Public Health and Health Services
Studies In Human Society: Policy and Administration, Sociology
Summary of the impact
The Cochrane Schizophrenia Systematic Review Group (CSzG) at the
University of Nottingham provided a knowledge platform upon which to
develop a novel Systematic Review Solutions company in China (SRS),
creating a new market in training of evidence-based medicine for
healthcare professionals, researchers and clinicians across China. Since
inception in 2009, SRS has generated income, created jobs, expanded to new
cities, improved knowledge of evidence-based healthcare, changed
prescribing practices and gained the support of Chinese Universities and
hospitals including the United Family Healthcare Group, China's largest
private hospital.
Underpinning research
Jun Xia (Director and Founder of SRS and Research Associate, Faculty of
Medicine and Health Sciences) joined the University of Nottingham Cochrane
Schizophrenia Group (UoN CSzG) in 2007 to conduct Systematic Reviews (SR).
Since her employment at Nottingham she has produced, and continues to
produce, a series of Cochrane Systematic Reviews investigating the
effectiveness of a variety of different schizophrenia treatments1-3
with the Nottingham Cochrane team leader Professor Clive Adams
(Co-ordinating Editor, UoN CSzG) and including the collaboration of
Professor Chungbo Li (Clinician and Satellite Member of CSzG) in Shanghai
Mental Health Centre (SMHC)4.
Xia's key research interest is how evidence-based medicine and Cochrane
methodology practices are shared across the UK and China. In 2008 Xia
investigated the reach of Chinese medical literature including its
accessibility in the West5 and identified a gap for an SR
training process to be put in place in China. This would allow for
effective transmission to other clinicians in China and also for shared
knowledge with the West. Xia's publication identified that there were
difficulties in communicating Western review methods to China and there
were few specialist SR training providers in China indicating a blank
canvas for a whole new market to be created. In 2008, the limited
provision of training opportunities in China included courses run only for
Chinese University medical students or a course run once annually by the
Chinese Cochrane Centre. This course could only support 100 students per
year and therefore was in high demand with long waiting lists. There was
therefore a significant gap here to run multiple training courses using a
course model from the University of Nottingham Cochrane Review Training
Course developed by Professor Adams6 (http://szg.cochrane.org/workshops-training-and-events).
The aim of a dedicated SR company was to provide a framework upon which
to conduct high quality systematic reviews on all aspects of healthcare
(using methodologies routinely conducted at University of Nottingham) to
directly inform clinical practice as well as providing high quality
training for healthcare professionals, clinicians, medical students and
other healthcare researchers. Therefore, as a direct result of her body of
work at Nottingham's CSzG and due to the opportunities afforded to her to
work with Professor Li with SMHC, Systematic Review Solutions (SRS) was
started by Jun Xia in Yantai in August 2009 with a view to initially
provide courses in Shanghai and Beijing.
The company currently specialises in services relevant to conducting
Cochrane SRs working in collaboration with experienced Cochrane reviewers,
statisticians and Cochrane groups. SRS services include training courses
in systematic reviewing and meta-analysis, commissioned systematic review
projects, trial searches, data extraction, data analysis and translation.
Thus, in addition to the success of the training courses provided, the
continued success of the company is reliant upon its ability to produce
publishable SR outputs for research scientists in China. In 2011 Xia
embarked on a PhD utilising her knowledge gained at Nottingham and through
her company, investigating access, activity and quality screening of
Chinese clinical trials in schizophrenia under the supervision of Adams.
This enhances the knowledge exchange between Xia's research and the
commercial impact of her company.
References to the research
Underpinning Research
1. Maayan N, Soares-Weiser K, Xia J, Adams, CE (2011) Antipsychotic
combinations for schizophrenia. Cochrane Database of Systematic
Reviews DOI: 10.1002/14651858.CD009005. IF: 5.703, Citations: 3
2. Xia J, Merinder Lars B, Belgamwar MR. (2012) Psychoeducation
for schizophrenia. Cochrane Database of Systematic Reviews DOI:
10.1002/14651858.CD002831.pub2. IF: 5.703, Citations: 60
3. Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B,
Maneeton N. (2013) Quetiapine versus typical antipsychotic medications for
schizophrenia. Cochrane Database of Systematic Reviews. DOI:
10.1002/14651858.CD007815.pub2. IF: 5.703, Citations: 1
4. Li C, Xia J, Wang J (2009). Risperidone dose for
schizophrenia. Cochrane Database of Systematic Reviews. DOI:
10.1002/14651858.CD007474.pub2. IF: 5.703, Citations: 13
5. Xia J, Wright J, Adams CE (2008). Five large Chinese
biomedical bibliographic databases: accessibility and coverage. Health
Information and Libraries Journal, 25, 55-61. DOI:
10.1111/j.1471-1842.2007.00734.x. IF: 0.662, Citations: 32.
Funding for Start Up of Company
£2000 by American donor Dr John Davis (Chicago University). Xia used the
funding received by Dr Davis to complete the registration of the company.
Key researchers
Jun Xia: Director and Founder of Systematic Review Solutions
(2009-present) and Research Associate, Faculty of Medicine & Health
Sciences (2007-present) Professor Clive Adams: Professor and Co-ordinating
Editor, Cochrane Schizophrenia Group, Faculty of Medicine & Health
Sciences (2007-present) Professor Chungbo Li: Clinician, Shanghai Mental
Health Centre, Satellite Member of Cochrane Schizophrenia Group in
Shanghai, China
Details of the impact
The start up and growth of a new international company
SRS was started in China in 2009 with initial funding for the company
(£2000), donated by Dr John Davis (USA), being used to complete the
registration of the company. The income generated by the completion of the
first SR training course held in Shanghai at the end of 2009 was
approximately £18,000 gross (£8,000 profit) indicating promising results
for company growth.
Since inception in late 2009, SRS has grown to employ four full-time and
one part- time senior and associate administrative staff based permanently
in China. Along with four part-time research assistants, 2 systematic
review trainers (all former attendees of the systematic review training
coursea) and 7 senior consultants from different backgrounds
including mental health research (Professor Adams, Nottingham), pain
research (Professor Wiffen, Oxford), drug and alcohol addiction (Steve
Lui), psychiatry (Mahesh Jayaram, Leeds), obstetrics (Masoud Afnan, Chief
Medical Officer for Beijing United Family Hospital), translation of
systematic review to NICE guidelines (John Rathbone, University of
Sheffield) and information specialist (Samantha Roberts, Nottinghamshire
Healthcare NHS Trust) demonstrating the company's international links.
To pilot SRS in other cities, early training courses were set up by Xia
in 2010 with support of Professor Li and Professor Adams, providing
additional Cochrane methodological review expertise and mental health
consultancy. As a consequence of this collaboration and training,
Professor Li's unit in SMHC is now a satellite group of the Cochrane
Schizophrenia Group in Nottinghamb, narrowing the gap between
knowledge exchange between China and the West as identified in Xia's
publication5. From its early beginnings, demand for training
courses has doubled in the last 3 years and courses are now held six times
yearly in Beijing, Shanghai and Xi'An generating £100k incomea.
Impact on International Commerce and Healthcare
SRS has achieved commercial impact by applying UoN CSzG methodology as a
template for doctors in China, using knowledge exchange to generate
economic impact across the Chinese Healthcare system, in particular in
Beijing and Shanghai. Highly skilled people have gained employment, for
example all research assistants and trainers in SRS were attendees of the
SR training, thus providing students the opportunity for high quality jobsa.
Additionally, clinicians are employing new methodologies to better
identify evidence-based treatment upon SR training in order to translate
this into better clinical practice (patients are treated based upon the
best evidence available)c. For example, attendee of the SRS
training course and Director of the Department of Clinical Psychiatry in
SMHC and Shanghai Jiao Tong University School of Medicine said:
`The SRS course changed my perception of evidence-based practice, it
made me more aware of searching up to date literature to inform my
clinical practice. For example, what are the most effective
interventions to treat people with schizophrenia. The course was
incredibly interactive, accessible and an asset to SMHC. I hope that it
continues to extend across China to help other clinicans be better
informed'c.
SRS has also shown economic impact through collaborations with industry
across China, including high quality knowledge transfer partnerships as
evidenced by support of Capital Medical University (Beijing) and United
Family Healthcare Group, the largest private hospital in Chinad.
Previous Chinese collaborations have also included University of
Nottingham Ningbo Campus (Ningbo) and hospitals including Shanghai Number
1 People's Hospital (Shanghai) and Beijing Xiyuan Traditional Chinese
Medicine Hospital (Beijing), Teaching Hospital of Xi'An, Medical Collage
(Xi'An). Private SR courses have also been given to clinicians in Beijing
Tiantan Hospital (one day course $5,000) and Shanghai Zhongshan Hospital
(£100 half an hour), Shanghai Number 1 People's Hospital (one day £1,500),
Shanghai Yangpu District Hospital (3 days £6,000) and researchers in
Yantai Binzhou Medical University. Internet SR courses began in May 2013
and, to date, on average each large 4 day training event generates
£15,000-18,000 gross with a single day training generating £4,000.
Impact on practitioners and services through increased uptake of
scientific training
Since 2009, SRS has been providing high quality intensive training for
healthcare professionals across China. These courses have gained in
popularity and have been extremely well received with 82% of attendees in
the largest course to date in 2013 rating the course as `excellent'e.
When asked how relevant each session is to their needs as clinicians, over
90% reported `very relevant'e. When asked how attendees found
about the course, 30% was based on word of mouth therefore the course has
generated positive reviews within the healthcare communityf.
Course attendees provided independent feedback on a popular online
bioscience website for professionals in medical, pharmaceutical, and
bioscience sector (Ding Xiang Yuan). Feedback was very positive,
including: `the programme is very well designed with a balanced
mixture of didactic lectures and hands-on workshops. Teaching staff are
not only the experts of this area, but also are very patient with
answering queries. They did a great job in teaching SR to both layman
and researchers in confined time 'g.
As well as being popular and well received within the Chinese medical
community, the training courses have also changed clinical practice in
various Chinese institutions, for example the change of prescription of
psychiatric medications for schizophrenia based upon up-to-date evidencec.
Systematic Review Project Management Service
Finally, started in August 2012 due to demand in China, a specialised
systematic review service was developed to assist healthcare
professionals, and in particular clinicians, in the development of their
Cochrane reviews and protocols in order to inform clinical practice. There
are currently 9 active reviews and 3 protocols on clinical topics such as
cancer, chemotherapy, septic shock, schizophrenia and pseudomyxoma (see
publications resulting from SRS input) generating a total income of
£50,000 (gross). In early 2013 alone, 5 SR reviews with authors based in
China were published as a result of input from SRS (Publications available
upon request): reviews that greatly benefited from SRS input.
Sources to corroborate the impact
a. Systematic Review Solutions (SRS) company registration and details
(http://www.review-solutions.cn/English/index.html).
Individual employment contracts available upon request (translation
required). Income figures per annum available.
b. Documentation corroborating China satellite company
c. Statement from Director (Physician-in-chief) from the Department of
Clinical Psychiatry (Shanghai Mental Health Centre) and Shanghai Jiao Tong
University School of Medicine describing how the training has improved
their practice and providing feedback on the course
d. Documentation from training days with company logos from: Universities
across China, Shanghai Mental Health Centre and United Family Healthcare
Group etc
e. Evaluation/feedback forms from training days including: clinicians,
health care professionals, researchers and policy makers to evaluate each
different training day
f. Internal statistics report (individual registration available upon
request). Translation required
g. Screenshot of online forum with examples of positive course feedback